WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that data from the Company's Phase III trial...
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the €œCompany€) today announced that it received a notice (the €œNotice€) on April 8, 2024 from the...
EGRX Investors Have Opportunity to Lead Eagle Pharma Securities Fraud Lawsuit
WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today provided an update on its bendamustine intellectual property...
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (œFDA) for rescue treatment of postoperative nausea and vomiting (œPONV)...
CEO and Founder Scott Tarriff Retires Chairman Michael Graves to Serve as Interim Executive Chairman WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals,...
WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the œCompany) today announced that it received a notice (the œNotice) on November 27, 2023 from...
WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (œEagle or the œCompany) today announced that it will be delaying the release of its third...
WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (œEagle or the œCompany) (Nasdaq: EGRX) today announced that the Company will release its third quarter 2023...